Loading data for CATX — first visit, this takes a few seconds.
Perspective Therapeutics, Inc. (CATX)
NYSE American: CATX
· Real-Time Price · USD
3.12
-0.04 (-1.27%)
At close: Sep 02, 2026, 8:00 PM
The price, the headline numbers and the latest news, in one place.
Perspective Therapeutics, Inc. (CATX) Stock Price, Analysis & Data
No data available
| Bid | 3.08 |
| Market Cap | 354M |
| Revenue (ttm) | 409K |
| Net Income (ttm) | -117M |
| 1.80 | |
| -1.33 | |
| n/a | |
| -3.04 | |
| P/B (ttm) | 1.09 |
| P/S (ttm) | 865.21 |
| Earnings Date | Nov 9, 2026 |
| Ask | 3.09 |
| Volume | 618,863 |
| Avg. Volume (20D) | 1,645,109 |
| Open | 3.16 |
| Previous Close | 3.16 |
| Day's Range | 3.07 - 3.17 |
| 52-Week Range | 1.96 - 6.16 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About CATX
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted r...
Industry Medical Devices
Sector Healthcare
IPO Date Nov 10, 2005
Employees 163
Stock Exchange NYSE American
Ticker Symbol CATX
Financial Performance
In 2025, Perspective Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -103.12M, an increase of 30.07%.
Financial StatementsEarnings Surprise
Perspective Therapeutics has released their quarterly earnings on Aug 10, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.22 exceeds estimates by 0.05, with 26.67% YoY growth.
Perspective Therapeutics, Inc. is scheduled to release its earnings on Nov 9, 2026, during market hours.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2